[go: up one dir, main page]

MX2024011086A - Compuestos tricíclicos sustituidos como inhibidores de parp y el uso de estos. - Google Patents

Compuestos tricíclicos sustituidos como inhibidores de parp y el uso de estos.

Info

Publication number
MX2024011086A
MX2024011086A MX2024011086A MX2024011086A MX2024011086A MX 2024011086 A MX2024011086 A MX 2024011086A MX 2024011086 A MX2024011086 A MX 2024011086A MX 2024011086 A MX2024011086 A MX 2024011086A MX 2024011086 A MX2024011086 A MX 2024011086A
Authority
MX
Mexico
Prior art keywords
parp inhibitors
substituted tricyclic
tricyclic compounds
compounds
parp
Prior art date
Application number
MX2024011086A
Other languages
English (en)
Inventor
Sui Xiong Cai
Ye Edward Tian
Xiaozhu Wang
Letian Zhang
Original Assignee
Impact Therapeutics Shanghai Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Impact Therapeutics Shanghai Inc filed Critical Impact Therapeutics Shanghai Inc
Publication of MX2024011086A publication Critical patent/MX2024011086A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan compuestos tricíclicos sustituidos como inhibidores de PARP y el uso de estos. Los compuestos representados mediante la Fórmula (I) como se muestra a continuación, en donde, el anillo Z, Z1, Z2, Z3, Z4, Z5, A1, A2, A3, L y Cy se definen en la presente descripción. Los compuestos de Fórmula I son inhibidores de PARP y, por lo tanto, son útiles en el tratamiento de enfermedades, trastornos y afecciones, tales como cáncer, que responden a la inhibición de la actividad de PARP. (Ver Fórmula I).
MX2024011086A 2022-03-11 2024-09-10 Compuestos tricíclicos sustituidos como inhibidores de parp y el uso de estos. MX2024011086A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202210260944 2022-03-11
CN202210448803 2022-04-24
CN202211219599 2022-09-30
CN202211505904 2022-11-28
PCT/CN2023/077988 WO2023169226A1 (en) 2022-03-11 2023-02-23 Substituted tricyclic compounds as parp inhibitors and the use thereof

Publications (1)

Publication Number Publication Date
MX2024011086A true MX2024011086A (es) 2024-12-06

Family

ID=87937164

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024011086A MX2024011086A (es) 2022-03-11 2024-09-10 Compuestos tricíclicos sustituidos como inhibidores de parp y el uso de estos.

Country Status (11)

Country Link
US (1) US20250215013A1 (es)
EP (1) EP4490161A1 (es)
JP (1) JP2025508122A (es)
KR (1) KR20240162104A (es)
CN (1) CN119013279A (es)
AU (1) AU2023229992A1 (es)
CA (1) CA3253468A1 (es)
IL (1) IL315586A (es)
MX (1) MX2024011086A (es)
TW (1) TW202400601A (es)
WO (1) WO2023169226A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023141290A1 (en) 2022-01-21 2023-07-27 Xinthera, Inc. Parp1 inhibitors and uses thereof
KR20240161147A (ko) 2022-03-14 2024-11-12 슬랩 파마슈티컬스 엘엘씨 다중 사이클릭 화합물
LT4355749T (lt) * 2022-04-28 2025-08-25 Xinthera, Inc. Tricikliniai parp1 inhibitoriai ir jų panaudojimo būdai
CN119110801A (zh) * 2022-05-07 2024-12-10 南京明德新药研发有限公司 选择性抑制parp1的氟代喹喔啉酮衍生物
KR20250088626A (ko) * 2022-11-10 2025-06-17 하이헤 바이오파마 컴패니 리미티드 융합된 삼환식 parp1 억제제, 이의 제조 방법 및 용도
WO2024179547A1 (en) * 2023-03-01 2024-09-06 Impact Therapeutics (Shanghai) , Inc. Substituted nitrogen-containing tricyclic compounds as parp inhibitors and the use thereof
WO2024255697A1 (zh) * 2023-06-13 2024-12-19 中国医药研究开发中心有限公司 含氮杂环类化合物及其医药用途
TW202525808A (zh) * 2023-09-13 2025-07-01 大陸商上海瑛派藥業有限公司 用作ｐａｒｐ１抑制劑的化合物、其用途及包含其之組合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPS137402A0 (en) * 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
CN101528704B (zh) * 2006-09-01 2014-04-09 生华生物科技股份有限公司 丝氨酸-苏氨酸蛋白激酶和parp调节剂
MA33053B1 (fr) * 2009-01-23 2012-02-01 Tadeka Pharmaceutical Company Ltd Inhibiteurs de la poly(adp-ribose) polymerase (parp)
EP2459561A1 (en) * 2009-07-30 2012-06-06 Takeda Pharmaceutical Company Limited Poly (adp-ribose) polymerase (parp) inhibitors
JP2018521033A (ja) * 2015-06-09 2018-08-02 ジェ イル ファーマシューティカル カンパニー リミテッド 三環式誘導体化合物、その製造方法及びそれを含む薬学的組成物
TW202309025A (zh) * 2021-04-19 2023-03-01 美商辛瑟拉股份有限公司 Parp1抑制劑及其用途

Also Published As

Publication number Publication date
WO2023169226A1 (en) 2023-09-14
US20250215013A1 (en) 2025-07-03
CA3253468A1 (en) 2023-09-14
IL315586A (en) 2024-11-01
TW202400601A (zh) 2024-01-01
KR20240162104A (ko) 2024-11-14
EP4490161A1 (en) 2025-01-15
JP2025508122A (ja) 2025-03-21
CN119013279A (zh) 2024-11-22
AU2023229992A1 (en) 2024-10-10

Similar Documents

Publication Publication Date Title
MX2024011086A (es) Compuestos tricíclicos sustituidos como inhibidores de parp y el uso de estos.
MX2024002425A (es) Compuestos tricíclicos sustituidos como inhibidores de parp y uso de estos.
ECSP22087539A (es) Inhibidores de kras tricíclicos fusionados
CL2024000043A1 (es) Compuestos tricíclicos como inhibidores de kras
MX2022006700A (es) Compuestos poliheterociclicos como inhibidores de mettl3.
ECSP22050936A (es) Compuestos tric?clicos sustituidos
CL2022001739A1 (es) Compuestos tricíclicos sustituidos
CO2021016594A2 (es) Pirroles tricíclicos condensados como moduladores de alfa-1 antitripsina
MX2020009372A (es) 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-onas sustituidas.
EA202190006A1 (ru) Пуриноновые соединения и их применение при лечении рака
CO2025015814A2 (es) Inhibidores de kras de 2-azabiciclo [2.2.1] heptano
BR112021017620A2 (pt) Compostos macrocíclicos
MX2021010122A (es) Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos.
CO6321241A2 (es) Derivados de 1,3,4- tiadiazol espiro condensados para la inhibicion de la actividad de quinesina (ksp)
ECSP045473A (es) Derivados de 1-(aminoalquil)-3-sulfonilindol y 1-aminoalquil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6
CL2023002223A1 (es) Inhibidores de cdk2 y métodos de uso de los mismos
CO2026000531A2 (es) Macrociclos para el tratamiento de enfermedades autoinmunitarias
SA522441650B1 (ar) مثبطات فوسفوينوسيتيد 3-كيناز الموضعية
BR112023012947A2 (pt) Inibidores de lrrk2
MX2023010317A (es) Derivados del indol como agentes serotonergicos utiles para el tratamiento de trastornos relacionados con los mismos.
MX2022006333A (es) Compuesto triheterociclico como inhibidor de jak y uso del mismo.
MX2024010344A (es) Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa
MX2024010216A (es) Compuestos de tienopirrolotriazina, su preparacion y su uso terapeutico.
CO2025002334A2 (es) Derivados arilos tricíclicos, y composiciones y métodos de los mismos
CO2021000782A2 (es) Agentes inhibidores de ask1